Trials / Completed
CompletedNCT05355935
A Study to Investigate the Effects of Brensocatib on QT Interval in Healthy Participants
A Two-part, Phase I, Double-blind, Placebo- and Positive-controlled Crossover Study to Investigate the Effects of Brensocatib on QT Interval in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Insmed Incorporated · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The study has 2 Parts: The primary purpose of Part 1 is to determine the supratherapeutic dose of brensocatib to be used in Part 2 of the study. The primary purpose of Part 2 is to assess brensocatib's potential for prolonging the QT interval.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Brensocatib | Oral tablet. |
| DRUG | Moxifloxacin | Oral tablet. |
| DRUG | Placebo | Oral tablet. |
Timeline
- Start date
- 2022-04-27
- Primary completion
- 2022-10-07
- Completion
- 2022-10-07
- First posted
- 2022-05-02
- Last updated
- 2023-03-27
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05355935. Inclusion in this directory is not an endorsement.